Shares of CELLECT BIOTECH/S (NASDAQ:APOP) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus price target of $14.00 for the company and are expecting that the company will post ($0.28) EPS for the current quarter, according to Zacks. Zacks has also given CELLECT BIOTECH/S an industry rank of 103 out of 255 based on the ratings given to its competitors.
A number of research analysts have recently commented on APOP shares. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of CELLECT BIOTECH/S in a report on Wednesday, August 29th. ValuEngine upgraded CELLECT BIOTECH/S from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th. Finally, Zacks Investment Research upgraded CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $8.25 target price for the company in a research note on Thursday, May 31st.
CELLECT BIOTECH/S stock traded down $0.04 during midday trading on Wednesday, reaching $4.98. 3,000 shares of the company were exchanged, compared to its average volume of 8,895. The stock has a market cap of $27.31 million, a PE ratio of -3.41 and a beta of 3.66. CELLECT BIOTECH/S has a 1 year low of $4.40 and a 1 year high of $13.50.
CELLECT BIOTECH/S (NASDAQ:APOP) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. equities research analysts predict that CELLECT BIOTECH/S will post -0.98 EPS for the current fiscal year.
About CELLECT BIOTECH/S
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Featured Article: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.